PCM
IBER

Pinz Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Pinz Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,670
Closed -$84K – 317
2021
Q4 		$84K Buy
+8,670
New +$84.3K 0.03% 267

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Pinz Capital Management's IBER Position: Q1 2022 in Review

Pinz Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2022, closing a stake of 8,670 shares — an estimated $84K sold.

Pinz Capital Management first reported a position in IBER in Q4 2021 and held it in 1 quarter. The position peaked at $84K in Q4 2021. 48 funds tracked by Wall St. Rank hold IBER as of Q1 2022.

  • Pinz Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Pinz Capital Management sold 8,670 Ibere Pharmaceuticals shares in Q1 2022, an estimated $84K.
  • Pinz Capital Management first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Pinz Capital Management's Ibere Pharmaceuticals position peaked at $84K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2022.

Based on Pinz Capital Management's 13F filing for Q1 2022, filed 16 May 2022.